Skip to main content

Realizing the benefits of gene silencing – Novel HDAC6 inhibitor for the treatment of inflammatory diseases

Ref-Nr: TA-B73271 | B77007


Kurzfassung

  • ‍Oral HDAC6 inhibitor with superior specificity
  • Anti-inflammatory effect in in vivo arthritis model
  • Alternative to first line anti-inflammatory drugs

 

 


Hintergrund

Inhibiting the action of histone deacetylases (HDAC) has emerged as a promising therapeutic approach in the treatment of many disorders, e.g. hematopoietic malignancies, with several selective HDAC inhibitors (HDACi) already approved for the clinic. The balance between histone acetylation and deacetylation is a critical determinant for cell proliferation, cell-cycle regulation and apoptosis with mutations in genes encoding HDACs linked to aberrant gene expression. Supporting their known anti-inflammatory action is data suggesting their use in the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis. Here, current treatment regimens have limited efficacy, e.g. first-line NSAIDs (non-steroidal anti-inflammatory drugs) and severe side-effect profiles in the long-term, e.g. steroids. With its two functional catalytic domains and specific physiological roles, HDAC6 presents a promising therapeutic candidate.


Bilder & Videos


Lösung

We present Marbostat-100 as a new class of small molecule inhibitors of HDAC6. Marbostat-100 exhibits superior potency and specificity compared to HDAC6i Tubastatin A and pan-HDACi LBH589. In vivo data from an arthritis mouse model shows a significantly improved therapeutic response without any toxic side effects.

Treatment lowered the clinical score with reduced synovial inflammation and delayed cartilage degradation and bone erosion1. Its mode of action is restricted to inhibiting enzymatic activity thereby not destroying the protein.


Vorteile

  • Potent anti-inflammatory and anti-rheumatic effects as alternative to NSAIDs
  • Superior potency and specificity compared to competitive products
  • Selective inhibition of enzymatic activity limits potential off-site effects
  • Water solubility allows for oral application

Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Teststadium


Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr